<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Zenas Biopharma, Inc. Common Stock — News on 6ix</title>
    <link>https://6ix.com/company/zenas-biopharma-inc-common-stock</link>
    <description>Latest news and press releases for Zenas Biopharma, Inc. Common Stock on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Fri, 27 Mar 2026 04:12:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/zenas-biopharma-inc-common-stock" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835dd5878dffbe2df124adb.webp</url>
      <title>Zenas Biopharma, Inc. Common Stock</title>
      <link>https://6ix.com/company/zenas-biopharma-inc-common-stock</link>
    </image>
    <item>
      <title>Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million</title>
      <link>https://6ix.com/company/zenas-biopharma-inc-common-stock/news/zenas-biopharma-announces-pricing-of-concurrent-public-offerings-of-250percent-convertible-senior-notes-due-2032-and-common-stock-with-aggregate-gross-proceeds-of-dollar3000-million</link>
      <guid isPermaLink="true">https://6ix.com/company/zenas-biopharma-inc-common-stock/news/zenas-biopharma-announces-pricing-of-concurrent-public-offerings-of-250percent-convertible-senior-notes-due-2032-and-common-stock-with-aggregate-gross-proceeds-of-dollar3000-million</guid>
      <pubDate>Fri, 27 Mar 2026 04:12:00 GMT</pubDate>
      <description>WALTHAM, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced the pricing of its underwritten public offering of $200.0 million aggregate principal amount of its 2.50% convertible senior notes due 2032 (the “Convertibl</description>
    </item>
    <item>
      <title>Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock</title>
      <link>https://6ix.com/company/zenas-biopharma-inc-common-stock/news/zenas-biopharma-announces-proposed-concurrent-public-offerings-of-convertible-senior-notes-due-2032-and-common-stock</link>
      <guid isPermaLink="true">https://6ix.com/company/zenas-biopharma-inc-common-stock/news/zenas-biopharma-announces-proposed-concurrent-public-offerings-of-convertible-senior-notes-due-2032-and-common-stock</guid>
      <pubDate>Thu, 26 Mar 2026 20:01:00 GMT</pubDate>
      <description>WALTHAM, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that it has commenced underwritten public offerings of its convertible senior notes due 2032 (the “Convertible Notes” and such offering, the “Convertible No</description>
    </item>
    <item>
      <title>Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update</title>
      <link>https://6ix.com/company/zenas-biopharma-inc-common-stock/news/zenas-biopharma-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update</link>
      <guid isPermaLink="true">https://6ix.com/company/zenas-biopharma-inc-common-stock/news/zenas-biopharma-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update</guid>
      <pubDate>Mon, 16 Mar 2026 11:00:00 GMT</pubDate>
      <description>- Obexelimab marketing applications for the treatment of IgG4-RD expected to be submitted to the FDA in Q2 2026 and the EMA in H2 2026 based on the Phase 3 INDIGO trial results - - Topline results of the global Phase 2 SunStone trial of obexelimab in SLE expected in Q4 2026 - - New, half-life extended anti-CD-19 and FcγRIIb mAb (ZB014) progressing toward clinical development - - Global orelabrutinib Phase 3 trial for primary progressive multiple sclerosis (MS) ongoing; global Phase 3 trial for n</description>
    </item>
    <item>
      <title>Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026</title>
      <link>https://6ix.com/company/zenas-biopharma-inc-common-stock/news/zenas-biopharma-announces-breaking-platform-120500646</link>
      <guid isPermaLink="true">https://6ix.com/company/zenas-biopharma-inc-common-stock/news/zenas-biopharma-announces-breaking-platform-120500646</guid>
      <pubDate>Mon, 09 Feb 2026 12:05:00 GMT</pubDate>
      <description>- Obexelimab met the primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo over weeks 8 and 12 (p=0.0009) - - Separately announced 24-week data support the robust and durable activity of obexelimab and further validate its unique inhibitory mechanism of action - - Obexelimab was well tolerated, and no new safety signals were observed - WALTHAM, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or</description>
    </item>
    <item>
      <title>Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026</title>
      <link>https://6ix.com/company/zenas-biopharma-inc-common-stock/news/zenas-biopharma-present-guggenheim-emerging-120500369</link>
      <guid isPermaLink="true">https://6ix.com/company/zenas-biopharma-inc-common-stock/news/zenas-biopharma-present-guggenheim-emerging-120500369</guid>
      <pubDate>Wed, 04 Feb 2026 12:05:00 GMT</pubDate>
      <description>WALTHAM, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced management’s presentation at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 1:30 p.m. ET. A live webcast and archived replay of the Co</description>
    </item>
    <item>
      <title>Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)</title>
      <link>https://6ix.com/company/zenas-biopharma-inc-common-stock/news/zenas-biopharma-announces-inducement-grant-211500815</link>
      <guid isPermaLink="true">https://6ix.com/company/zenas-biopharma-inc-common-stock/news/zenas-biopharma-announces-inducement-grant-211500815</guid>
      <pubDate>Fri, 16 Jan 2026 21:15:00 GMT</pubDate>
      <description>WALTHAM, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced that on January 15, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase 100,000 shares of the Company’s common stock to a newly</description>
    </item>
    <item>
      <title>Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)</title>
      <link>https://6ix.com/company/zenas-biopharma-inc-common-stock/news/zenas-biopharma-announces-positive-results-120500416</link>
      <guid isPermaLink="true">https://6ix.com/company/zenas-biopharma-inc-common-stock/news/zenas-biopharma-announces-positive-results-120500416</guid>
      <pubDate>Mon, 05 Jan 2026 12:05:00 GMT</pubDate>
      <description>- Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction in risk of IgG4-RD flare - - Obexelimab also met and demonstrated statistically significant activity on all four key secondary efficacy endpoints - - Obexelimab was well tolerated and no new safety signals were observed - - Zenas anticipates submitting a Biologics License Application (BLA) to the FDA in the second quarter of 2026 and a Marketing Authorization Application</description>
    </item>
    <item>
      <title>Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
      <link>https://6ix.com/company/zenas-biopharma-inc-common-stock/news/zenas-biopharma-announces-inducement-grants-211500761</link>
      <guid isPermaLink="true">https://6ix.com/company/zenas-biopharma-inc-common-stock/news/zenas-biopharma-announces-inducement-grants-211500761</guid>
      <pubDate>Fri, 19 Dec 2025 21:15:00 GMT</pubDate>
      <description>WALTHAM, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that on December 15, 2025 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase 300,000 shares of t</description>
    </item>
    <item>
      <title>Zenas BioPharma’s Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus</title>
      <link>https://6ix.com/company/zenas-biopharma-inc-common-stock/news/zenas-biopharma-partner-innocare-pharma-120500619</link>
      <guid isPermaLink="true">https://6ix.com/company/zenas-biopharma-inc-common-stock/news/zenas-biopharma-partner-innocare-pharma-120500619</guid>
      <pubDate>Mon, 15 Dec 2025 12:05:00 GMT</pubDate>
      <description>- Orelabrutinib is the first BTK inhibitor to demonstrate significant clinical activity in a Phase 2 clinical trial for SLE - - Zenas acquired the exclusive right to develop, manufacture and commercialize orelabrutinib in the field of Multiple Sclerosis globally, and non-oncology fields in all territories outside Greater China and Southeast Asia, in October 2025 license agreement with InnoCare – WALTHAM, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” o</description>
    </item>
    <item>
      <title>Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update</title>
      <link>https://6ix.com/company/zenas-biopharma-inc-common-stock/news/zenas-biopharma-reports-third-quarter-120500738</link>
      <guid isPermaLink="true">https://6ix.com/company/zenas-biopharma-inc-common-stock/news/zenas-biopharma-reports-third-quarter-120500738</guid>
      <pubDate>Wed, 12 Nov 2025 12:05:00 GMT</pubDate>
      <description>- Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end 2025 - - Reported highly positive 12-week primary endpoint results from Phase 2 MoonStone trial of obexelimab in Relapsing MS (RMS) - - Secured development and commercialization rights for three autoimmune product candidates, including orelabrutinib, a BTK Inhibitor in Phase 3 development for progressive forms of Multiple Sclerosis (MS) - - Entered into obexelimab funding agr</description>
    </item>
    <item>
      <title>Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences</title>
      <link>https://6ix.com/company/zenas-biopharma-inc-common-stock/news/zenas-biopharma-present-upcoming-healthcare-120500786</link>
      <guid isPermaLink="true">https://6ix.com/company/zenas-biopharma-inc-common-stock/news/zenas-biopharma-present-upcoming-healthcare-120500786</guid>
      <pubDate>Tue, 11 Nov 2025 12:05:00 GMT</pubDate>
      <description>WALTHAM, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced management’s presentations at the following investor conferences: Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025, at 11:00 a.m. GMT8th Annual Ev</description>
    </item>
    <item>
      <title>Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis</title>
      <link>https://6ix.com/company/zenas-biopharma-inc-common-stock/news/zenas-biopharma-announces-positive-results-110500218</link>
      <guid isPermaLink="true">https://6ix.com/company/zenas-biopharma-inc-common-stock/news/zenas-biopharma-announces-positive-results-110500218</guid>
      <pubDate>Mon, 27 Oct 2025 11:05:00 GMT</pubDate>
      <description>- Obexelimab met primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo, p=0.0009 - WALTHAM, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced positive result</description>
    </item>
    <item>
      <title>Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis</title>
      <link>https://6ix.com/company/zenas-biopharma-inc-common-stock/news/zenas-biopharma-innocare-pharma-announce-090000379</link>
      <guid isPermaLink="true">https://6ix.com/company/zenas-biopharma-inc-common-stock/news/zenas-biopharma-innocare-pharma-announce-090000379</guid>
      <pubDate>Wed, 08 Oct 2025 09:00:00 GMT</pubDate>
      <description>- Orelabrutinib, a highly selective CNS-penetrant, oral small molecule Bruton’s Tyrosine Kinase (BTK) inhibitor with best-in-class potential now in Phase 3 development for progressive forms of Multiple Sclerosis (MS) - - Pivotal Phase 3 clinical trial evaluating orelabrutinib in patients with Primary Progressive MS (PPMS) initiated; Pivotal Phase 3 clinical trial in patients with Secondary Progressive MS (SPMS) expected to initiate in 1Q 2026 - - A novel oral IL-17AA/AF inhibitor, and an oral, b</description>
    </item>
    <item>
      <title>Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million</title>
      <link>https://6ix.com/company/zenas-biopharma-inc-common-stock/news/royalty-pharma-and-zenas-biopharma-enter-into-obexelimab-funding-agreement-for-up-to-dollar300-million</link>
      <guid isPermaLink="true">https://6ix.com/company/zenas-biopharma-inc-common-stock/news/royalty-pharma-and-zenas-biopharma-enter-into-obexelimab-funding-agreement-for-up-to-dollar300-million</guid>
      <pubDate>Tue, 02 Sep 2025 11:15:00 GMT</pubDate>
      <description>Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related DiseaseAdditional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for the treatment of IgG4-Related Disease NEW YORK and WALTHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Zenas BioPharma, Inc. (Nasdaq: ZBIO) today announced that Royalty Pharma will provide up to $300 million in funding in</description>
    </item>
    <item>
      <title>Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million</title>
      <link>https://6ix.com/company/zenas-biopharma-inc-common-stock/news/zenas-biopharma-royalty-pharma-enter-110500499</link>
      <guid isPermaLink="true">https://6ix.com/company/zenas-biopharma-inc-common-stock/news/zenas-biopharma-royalty-pharma-enter-110500499</guid>
      <pubDate>Tue, 02 Sep 2025 11:05:00 GMT</pubDate>
      <description>- Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease - - Additional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for the treatment of IgG4-Related Disease - WALTHAM, Mass. and New York, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (Nasdaq: ZBIO), and Royalty Pharma plc (Nasdaq: RPRX) today announced that Royalty Pharma will provide up to $300 million in f</description>
    </item>
    <item>
      <title>Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates</title>
      <link>https://6ix.com/company/zenas-biopharma-inc-common-stock/news/zenas-biopharma-reports-second-quarter-110500477</link>
      <guid isPermaLink="true">https://6ix.com/company/zenas-biopharma-inc-common-stock/news/zenas-biopharma-reports-second-quarter-110500477</guid>
      <pubDate>Tue, 12 Aug 2025 11:05:00 GMT</pubDate>
      <description>- Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 - - Completed enrollment of Phase 2 MoonStone trial in Relapsing Multiple Sclerosis; results expected early in the fourth quarter 2025 - - Enrollment of Phase 2 SunStone trial in Systemic Lupus Erythematosus expected to be completed by year-end 2025; topline results expected mid-2026 - - Cash, cash equivalents and investments of $274.9 million as of June 30, 2025, expected to pr</description>
    </item>
    <item>
      <title>Zenas BioPharma to Present at the Jefferies Global Healthcare Conference</title>
      <link>https://6ix.com/company/zenas-biopharma-inc-common-stock/news/zenas-biopharma-present-jefferies-global-110500619</link>
      <guid isPermaLink="true">https://6ix.com/company/zenas-biopharma-inc-common-stock/news/zenas-biopharma-present-jefferies-global-110500619</guid>
      <pubDate>Thu, 29 May 2025 11:05:00 GMT</pubDate>
      <description>WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced management’s presentation at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 1:25 p.m. ET. A live webcast and archived replay of the Company’s presentation can be accessed under “Events an</description>
    </item>
    <item>
      <title>Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates</title>
      <link>https://6ix.com/company/zenas-biopharma-inc-common-stock/news/zenas-biopharma-reports-first-quarter-110500101</link>
      <guid isPermaLink="true">https://6ix.com/company/zenas-biopharma-inc-common-stock/news/zenas-biopharma-reports-first-quarter-110500101</guid>
      <pubDate>Thu, 15 May 2025 11:05:00 GMT</pubDate>
      <description>- Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 - - Phase 2 MoonStone trial in Relapsing Multiple Sclerosis enrollment concluding; topline results expected early in the fourth quarter 2025 - - Enrollment of Phase 2 SunStone trial in Systemic Lupus Erythematosus expected to be completed by year-end 2025; topline results expected mid-2026 - - Strengthened leadership team with appointments of Lisa von Moltke, M.D., Head of Resea</description>
    </item>
    <item>
      <title>Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer</title>
      <link>https://6ix.com/company/zenas-biopharma-inc-common-stock/news/zenas-biopharma-appoints-haley-laken-110500588</link>
      <guid isPermaLink="true">https://6ix.com/company/zenas-biopharma-inc-common-stock/news/zenas-biopharma-appoints-haley-laken-110500588</guid>
      <pubDate>Mon, 07 Apr 2025 11:05:00 GMT</pubDate>
      <description>Dr. Laken brings over 25 years of leadership experience in research, development operations, scientific assessment and strategyWALTHAM, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the appointment of Haley Laken, Ph.D., as Chief Scientific Officer (CSO). Dr. Laken</description>
    </item>
    <item>
      <title>Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer</title>
      <link>https://6ix.com/company/zenas-biopharma-inc-common-stock/news/zenas-biopharma-appoints-lisa-von-110500656</link>
      <guid isPermaLink="true">https://6ix.com/company/zenas-biopharma-inc-common-stock/news/zenas-biopharma-appoints-lisa-von-110500656</guid>
      <pubDate>Mon, 17 Mar 2025 11:05:00 GMT</pubDate>
      <description>–Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory success at both large and emerging global biopharmaceutical companies– WALTHAM, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the appointmen</description>
    </item>
  </channel>
</rss>